The Indian pharmaceutical industry has recorded a revenue of Rs 43424 crore with 13.7 per cent for the first nine months of the fiscal 2009-10, reveals a monthly report from the market surveillance and electronics infrastructure development firm, AIOCD Pharmasofttech AWACS. The revenue for the month of December 2009 was reported at Rs 3766 crore with a growth rate of 14.4 per cent, as per a report created by the firm through its market surveillance product - PharmaTrac.
The revenue of the top ten firms contributed Rs 1596 crore out of the total market in the month of December. Cipla remains the top company in the list with a revenue of Rs 230 crore for the month with 17.6 per cent growth rate and a total of Rs 2377 crore for the first three quarters of the financial year. Ranbaxy stands second in the list with Rs 187 crore revenue for the month with 7.2 per cent growth rate and Rs 2210 crore with 7.8 per cent growth for the first nine months of the quarter.
"We are deeply thankful to all the companies who have participated in the validation exercise - covering almost 64 per cent in total market share of the pharma market. Our access with the retailers, wholesalers and the pharma firms helps us to get the figures more accurate and thus we are able to deliver reports with more precision," said Ameesh Masurekar, director, AIOCD Pharmasofttech AWACS. There are have been several changes to company rankings and value, although overall market and growth rate has broadly remained the same.
The companies - GlaxoSmithKline, Piramal Healthcare, Sun Pharmaceuticals, Zydus Cadila, Lupin, Mankind Pharma, Alkem Lab, Aristo Pharma - follows Cipla and Ranbaxy in the ranking list.
However, Mankind, Aristo, Lupin and Alkem reported as growing at more pace than the top five companies, with more than 18 to 20 per cent in December. Mankind, which has a strong sales strategy with reach to remote areas in the country has also recorded a growth of 21.7 per cent in the nine months of current fiscal, shows the report.
Out of the Rs 43424 crore market as depicted in the first nine months of 2009-10, expectorants and antitussives tops the most selling products with a market size of Rs 1286 crore occupying a market share of three per cent reporting a growth rate of 8.6 per cent. Amoxycillin + Clavulanic Acid has the second highest market, with a market revenue of Rs 676 crore holding 1.6 per cent of the market share and growing at 20.6 per cent in the period.
Calcium with calcitriol (Vitamin D3) and other ingredients follows the other two products with Rs 624 crore market revenue with a market share of 1.4 per cent and 11.7 per cent growth rate. Cefixime, other iron combinations including Liver extracts and folic acid, atorvastatin, other multivitamins with minerals, ceftriaxone, cefpodoxime and diclofenac are the products in the top ten most marketed products in the period in the country.